Welcome to Genescient!

Genescient is a new generation biotechnology company that combines evolutionary genomics with massive selective screening to analyze and exploit the genetics of model animal and human whole genomes. This enables Genescient to develop novel therapeutics that target the chronic diseases of aging.

Our Publications

  • Adaptation, Aging, and Genomic Information

    Aging is not simply an accumulation of damage or inappropriate higher-order signaling. Aging occurs because of the extensive absence of adaptive genomic information

  • Evolution of ageing since Darwin

    Evolutionary biology provides the only cogent, formally developed, and experimentally corroborated theory for biological ageing. In this essay, we supply a brisk run through the highlights of evolutionary research on the biology of ageing.

In The Press

  • Genescient Receives Additional Angel Funding

    Genescient Corporation, a California genomic-health biotechnology company, received $500,000 in new angel investment, to help commercialize the company’s technology and to fund further research.

  • Genescient Chairman to Speak at Singularity Summit 2009

    Gregory Benford, Chairman of the Board of Genescient Corporation, will discuss Genescient’s approach to expanded longevity and will discuss some of its latest results, at The Singularity Summit 09.

  • Caffeine Cuts Male Mating Success

    Genescient study suggests that, when long-term effects are considered, two commonly ingested stimulants are not created equal. Caffeine consistently impaired mating success in Genescient’s experiments, as-well-as survival and female reproduction. Theobromine was benign.